Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings

A panel of experts on multiple myeloma introduce themselves and discuss the initial process of identifying patients who are potential candidates for CAR T-cell therapy.

Focusing on the transition of patients from community practices to academic centers, the panel discusses the initial evaluation and treatment processes, focusing on bridging therapy for patients awaiting CAR T.

Myeloma specialists discuss their approaches to determining the optimal timing for leukapheresis for patients awaiting CAR T-cell therapy.

Experts on multiple myeloma provide clinical insights on how they triage and prioritize patients to best utilize available resources.

Members of the panel discuss their criteria for determining when a patient is ready to transition back to community oncologists after they receive CAR T-cell therapy.

A panel of oncologists in academic and community settings discuss patient monitoring practices following CAR T-cell infusions, with a focus on neurotoxicities.

The panel provides clinical insights on talking with patients about complications associated with CAR T-cell therapy.

Experts on multiple myeloma provide clinical insights on unmet needs associated with CAR T-cell therapy, focusing on patient access across academic and community settings.

The panel concludes its discussion with insights on practices for educating health care teams on CAR T-cell therapy administration, highlighting the evolving role of advanced practice providers.

Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.